Glutathione transport, oxidative stress and lung injury

谷胱甘肽转运、氧化应激和肺损伤

基本信息

  • 批准号:
    6835212
  • 负责人:
  • 金额:
    $ 34.11万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-12-15 至 2007-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The overall goal of this application is to understand the role of glutathione (GSH) transport in the subcellular mechanisms of oxidative lung damage. (CF) is a genetic disorder that results in persistent lung inflammation and chronic infection that is implicated in progressive lung injury. Exciting preliminary studies indicate that the genetic defect in the cystic fibrosis transmembrane conductance regulator (CFTR) produces an antioxidant imbalance by decreasing GSH transport into the pulmonary epithelial lining fluid (ELF) and possibly altering GSH transport into the mitochondria. Modulation of GSH transport by the CFTR gene may render the CF patient vulnerable both exogenous and endogenous oxidative stress and thus contribute to the CF pulmonary phenotype. Although evidence exists supporting the role of oxidative stress in the lungs of CF patients, the etiologic and pathogenic relationship between the CFTR gene deficits to oxidative stress has yet to be established. Proposed experiments will delineate the relationship between altered GSH transport and oxidative stress in pulmonary injury associated with CF. The CFTR KO mouse provides a unique way to study pathophysiological mechanisms by which defective GSH transport contributes to antioxidant imbalance and oxidative stress responses in the lung. The CFTR KO recapitulates pulmonary GSH imbalance and oxidative stress of CF patients. It is hypothesized that altered lung GSH transport and metabolism contributes to exaggerated pulmonary oxidative injury and altered host defense. The hypothesis is addressed by the AIMS: (1) To characterize the altered GSH transport, metabolism, utilization, and associated oxidative stress in the lungs of the CFTR KO; (2) Determine whether modulation of GSH transporters can correct the GSH imbalance, oxidative stress, and host defense responses in the CFTR KO; (3) Determine if CFTR KO mice with altered GSH transport are more sensitive to acute lung injury. To accomplish the above aims, the steady-state levels of GSH, GSSG, and GSNO and associated enzyme activities are determined in the lungs of CFTR KO and wild type mice. In addition, markers of oxidative damage to protein, lipid, and DNA are quantitated. GSH transport through ABC cassette proteins will be characterized, modulated, and correlated with changes in oxidative stress and host defense. Lung injury models of infection and oxidative stress are utilized to assess the role of altered GSH transport in lung injury responses. Catalytic antioxidant metalloporphyrins and inhaled GSH are employed to reduce oxidant burden and correct the exaggerated pulmonary oxidative injury response in CF. These studies may emphasize the potential adverse effects of oxidative stress from oxidant air pollutants in sensitive populations with pre-existing lung disease, since a large number of pulmonary diseases (including COPD, ARDS, asthma and pulmonary fibrosis) also have deficits pulmonary ELF GSH
描述(由申请人提供):本申请的总体目标是了解谷胱甘肽(GSH)转运在氧化性肺损伤的亚细胞机制中的作用。(Cf)是一种遗传性疾病,会导致持续性肺部炎症和慢性感染,并与进行性肺损伤有关。令人振奋的初步研究表明,囊性纤维化跨膜电导调节器(CFTR)的遗传缺陷通过减少GSH向肺上皮衬底液(ELF)的转运,并可能改变GSH向线粒体的转运,从而产生抗氧化失衡。CFTR基因对GSH转运的调节可能使CF患者容易受到外源性和内源性氧化应激的影响,从而导致CF肺表型。虽然有证据支持氧化应激在CF患者肺中的作用,但CFTR基因缺陷与氧化应激之间的病因和发病关系尚未建立。拟议中的实验将描述与CF相关的肺损伤中GSH转运改变和氧化应激之间的关系。CFTRKO小鼠提供了一种独特的方法来研究GSH运输缺陷导致肺内抗氧化剂失衡和氧化应激反应的病理生理机制。CFTRKO重述了CF患者的肺GSH失衡和氧化应激。据推测,肺GSH转运和代谢的改变导致了肺氧化损伤的加重和宿主防御的改变。该假说旨在:(1)表征CFTRKO中改变的GSH运输、代谢、利用和相关的氧化应激;(2)确定GSH转运体的调节是否可以纠正CFTRKO中的GSH失衡、氧化应激和宿主防御反应;(3)确定GSH转运改变的CFTRKO小鼠是否对急性肺损伤更敏感。为了达到上述目的,我们测定了CFTRKO和野生型小鼠肺中GSH、GSSG和GSNO的稳态水平和相关酶的活性。此外,还对蛋白质、脂肪和DNA的氧化损伤标记物进行了定量。谷胱甘肽通过ABC盒蛋白的运输将被表征、调节,并与氧化应激和宿主防御的变化相关。肺损伤模型的感染和氧化应激被用来评估改变的GSH运输在肺损伤反应中的作用。使用催化抗氧化剂金属卟啉和吸入GSH来减轻氧化负荷,纠正被夸大的肺氧化损伤反应。这些研究可能会强调氧化性空气污染物对患有肺部疾病的敏感人群的潜在不利影响,因为大量的肺部疾病(包括COPD、ARDS、哮喘和肺纤维化)也存在肺ELF GSH缺陷

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Brian J Day其他文献

Nebulized Thiocyanate Dramatically Improves Lung Infection Outcomes in Mice
  • DOI:
    10.1016/j.freeradbiomed.2012.10.244
  • 发表时间:
    2012-11-01
  • 期刊:
  • 影响因子:
  • 作者:
    Joshua D Chandler;Elysia Min;Jie Huang;David P Nichols;Brian J Day
  • 通讯作者:
    Brian J Day

Brian J Day的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Brian J Day', 18)}}的其他基金

Selenocyanate as a novel treatment of cystic fibrosis lung disease
硒氰酸盐作为囊性纤维化肺病的新型治疗方法
  • 批准号:
    10312798
  • 财政年份:
    2019
  • 资助金额:
    $ 34.11万
  • 项目类别:
Optimization of AEOL10150 treatment of sulfur mustard-induced lung toxidrome in a pig model
AEOL10150 治疗猪芥子气肺中毒模型的优化
  • 批准号:
    10626938
  • 财政年份:
    2018
  • 资助金额:
    $ 34.11万
  • 项目类别:
Optimization of AEOL10150 treatment of sulfur mustard-induced lung toxidrome in a pig model
AEOL10150 治疗猪芥子气肺中毒模型的优化
  • 批准号:
    10434637
  • 财政年份:
    2018
  • 资助金额:
    $ 34.11万
  • 项目类别:
Optimization of AEOL10150 treatment of sulfur mustard-induced lung toxidrome in a pig model
AEOL10150 治疗猪芥子气肺中毒模型的优化
  • 批准号:
    9769732
  • 财政年份:
    2018
  • 资助金额:
    $ 34.11万
  • 项目类别:
Optimization of AEOL10150 treatment of sulfur mustard-induced lung toxidrome in a pig model
AEOL10150 治疗猪芥子气肺中毒模型的优化
  • 批准号:
    9938593
  • 财政年份:
    2018
  • 资助金额:
    $ 34.11万
  • 项目类别:
Targeting Oxidative Stress in Chronic Beryllium Disease
针对慢性铍病的氧化应激
  • 批准号:
    8450168
  • 财政年份:
    2009
  • 资助金额:
    $ 34.11万
  • 项目类别:
Targeting Oxidative Stress in Chronic Beryllium Disease
针对慢性铍病的氧化应激
  • 批准号:
    7749333
  • 财政年份:
    2009
  • 资助金额:
    $ 34.11万
  • 项目类别:
Targeting Oxidative Stress in Chronic Beryllium Disease
针对慢性铍病的氧化应激
  • 批准号:
    8053472
  • 财政年份:
    2009
  • 资助金额:
    $ 34.11万
  • 项目类别:
Targeting Oxidative Stress in Chronic Beryllium Disease
针对慢性铍病的氧化应激
  • 批准号:
    8246509
  • 财政年份:
    2009
  • 资助金额:
    $ 34.11万
  • 项目类别:
Adaptive glutathione responses to cigarette smoke in COPD
慢性阻塞性肺病患者对香烟烟雾的适应性谷胱甘肽反应
  • 批准号:
    7383987
  • 财政年份:
    2007
  • 资助金额:
    $ 34.11万
  • 项目类别:

相似海外基金

Rapid detection of Pseudomonas aeruginosa in people with cystic fibrosis
快速检测囊性纤维化患者中的铜绿假单胞菌
  • 批准号:
    10103495
  • 财政年份:
    2024
  • 资助金额:
    $ 34.11万
  • 项目类别:
    Collaborative R&D
Rational optimization of combinatorial therapies for the treatment of rare cystic fibrosis variants
合理优化治疗罕见囊性纤维化变异的组合疗法
  • 批准号:
    10736732
  • 财政年份:
    2023
  • 资助金额:
    $ 34.11万
  • 项目类别:
Pulmonary delivery of base editors for gene therapy of cystic fibrosis with nonsense mutations
肺部递送碱基编辑器用于无义突变囊性纤维化的基因治疗
  • 批准号:
    488681
  • 财政年份:
    2023
  • 资助金额:
    $ 34.11万
  • 项目类别:
    Operating Grants
Analysis of synthetic derivatives with reduced lipophilicity as candidate potentiators towards better treatment alternatives for Cystic Fibrosis
分析亲脂性降低的合成衍生物作为候选增效剂,以获得更好的囊性纤维化治疗替代方案
  • 批准号:
    481159
  • 财政年份:
    2023
  • 资助金额:
    $ 34.11万
  • 项目类别:
Developing Gene Editing Therapeutics, Biodegradable Polymeric Delivery Vehicles, and High-throughput Platforms for the Treatment of Cystic Fibrosis
开发用于治疗囊性纤维化的基因编辑疗法、可生物降解的聚合物递送载体和高通量平台
  • 批准号:
    10836095
  • 财政年份:
    2023
  • 资助金额:
    $ 34.11万
  • 项目类别:
A Ginsenoside TMEM16A Potentiator for Cystic Fibrosis
人参皂苷 TMEM16A 治疗囊性纤维化的增效剂
  • 批准号:
    10574384
  • 财政年份:
    2023
  • 资助金额:
    $ 34.11万
  • 项目类别:
Computationally-Inspired Design of Non-Viral Gene Delivery Vehicles for mRNA-Based Cystic Fibrosis Therapies
用于基于 mRNA 的囊性纤维化治疗的非病毒基因传递载体的计算启发设计
  • 批准号:
    10760605
  • 财政年份:
    2023
  • 资助金额:
    $ 34.11万
  • 项目类别:
Health Outcomes of Parents with Cystic Fibrosis (HOPe:CF)
患有囊性纤维化的父母的健康结果 (HOPe:CF)
  • 批准号:
    10581321
  • 财政年份:
    2023
  • 资助金额:
    $ 34.11万
  • 项目类别:
Preparation for lung transplant discussions and decisions among people with cystic fibrosis
囊性纤维化患者肺移植讨论和决策的准备
  • 批准号:
    10657027
  • 财政年份:
    2023
  • 资助金额:
    $ 34.11万
  • 项目类别:
The role of anaerobic microbiota in cystic fibrosis airway disease trajectory
厌氧微生物群在囊性纤维化气道疾病轨迹中的作用
  • 批准号:
    10716654
  • 财政年份:
    2023
  • 资助金额:
    $ 34.11万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了